(Q30442540)

English

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

0 references

phase II clinical trial

0 references

0 references

endometrial cancer

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Deborah J Stearns-Kurosawa

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

D Scott McMeekin

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Michael W Sill

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Doris Benbrook

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Kathleen M Darcy

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Lynne Eaton

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

S Diane Yamada

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Gynecologic Oncology Group

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

0 references

publication date

15 February 2007

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Gynecologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

105

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

508-516

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Cancer statistics, 2006

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Properties of thalidomide and its analogues: implications for anticancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Sex steroid-dependent angiogenesis in uterine endometrial cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Clinical translation of angiogenesis inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Angiogenesis in endometrial cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Regulation and functions of the protein C anticoagulant pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Independent prognostic importance of microvessel density in endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Thalidomide is an inhibitor of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

20 June 2018

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Plasma levels of endothelial protein C receptor respond to anticoagulant treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Optimal flexible designs in phase II clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1931832

26 November 2018

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Involvement of platelets in tumour angiogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Cytosol Vascular Endothelial Growth Factor in Endometrial Carcinoma: Correlation with Disease-Free Survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.01.019

7 January 2021

The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/17306350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Expression of basic fibroblastic growth factor and microvessel density in endometrial carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/17306350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]

1 reference

https://pubmed.ncbi.nlm.nih.gov/17306350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/17306350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17306350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/17306350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2007.01.019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17306350%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30442540&oldid=1957313834"